Optimization of approaches to the treatment of obesity in patients with type 2 diabetes mellitus

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Diabetes mellitus (DM) and obesity are one of the most common combinations in the structure of comorbid pathology, which is confirmed by numerous epidemiological data. Both of these diseases are based on primary insulin resistance and develop with the participation of largely identical pathological mechanisms. The relationship of pathogenetic mechanisms allows using an integrated approach to prescribing drugs and achieving target glycemic control and weight loss simultaneously. The article presents the main groups of drugs used in the treatment of obesity in diabetic patients with the determination of optimal combinations depending on the characteristics of the DM course, its complications and concomitant diseases.

Full Text

Restricted Access

About the authors

I. A. Kurnikova

Patrice Lumumba Peoples’ Friendship University of Russia; Russian Medical Academy of Continuous Professional Education

Author for correspondence.
Email: curnikova@yandex.ru
ORCID iD: 0000-0002-5712-9679
SPIN-code: 8579-9455

Dr. Sci. (Med.), Professor at the Department of Hospital Therapy with Courses in Endocrinology, Hematology and Clinical Laboratory Diagnostics of the Medical Institute

Russian Federation, Moscow; Moscow

M. S. Chekalina

Central Clinical Hospital of Civil Aviation

Email: curnikova@yandex.ru
ORCID iD: 0009-0008-5231-8164
Russian Federation, Moscow

A. U. Ualikhanova

Patrice Lumumba Peoples’ Friendship University of Russia

Email: curnikova@yandex.ru
ORCID iD: 0000-0002-6127-7383
Russian Federation, Moscow

References

  1. NCD Risk Factor Collaboration (29 February 2024). «Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults». Lancet. 2024;403(10431):1027–50. doi: 10.1016/S0140-6736(23)02750-2.ISSN0140-6736.
  2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627–42. URL: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(17)32129-3/fulltext.
  3. Юсенко С.Р., Зубкова Т.С., Сорокин А.С., Халтурина Д.А. Ожирение в России: динамика распространенности и половозрастная структура с конца XX века. Общественное здоровье. 2024;3(4):17–29. [Yusenko S.R., Zubkova T.S., Sorokin A.S., Khaltourina D.A. Obesity in Russia: prevalence dynamics and sex and age structure since the end of the 20th century. Public health. 2024;3(4):17–29. (In Russ.)]. Doi: 10.21045/ 2782 1676 2024 4 3-17-29.
  4. Дедов И.И., Мокрышева Н.Г., Мельниченко Г.А. и др. Ожирение. Клинические рекомендации. Consilium Medicum. 2021;23(4):311–25. [Dedov I.I., Mokrysheva N.G., Mel’nichenko G.A., et al. Obesity. Clinical guidelines. Consilium Medicum. 2021;23(4):311–25. (In Russ.)]. doi: 10.26442/20751753.2021.4.200832.
  5. Magliano D.J., Boyko E.J. IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS [Internet]. 10th ed. Brussels: International Diabetes Federation; 2021. [PMID: 35914061].
  6. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 11-й выпуск. М., 2023. [Algorithms of specialized medical care for patients with diabetes mellitus. Ed. I.I. Dedov, M.V. Shestakova, A.Y. Mayorov. 11th edition. M., 2023. (In Russ.)]. doi: 10.14341/DM13042.
  7. Fahed G., Aoun L., Bou Zerdan M., et al. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022;23(2):786. doi: 10.3390/ijms23020786.
  8. Rochlani Y., Pothineni N.V., Kovelamudi S., Mehta J.L. Metabolic syndrome: pathophysiology, management, and modulation by natural compounds. Ther Adv Cardiovasc Dis. 2017;11(8):215–25. doi: 10.1177/1753944717711379.
  9. Bluher M. «Metabolically Healthy Obesity». Endocrine Reviews. 2020;41(3):bnaa004. doi: 10.1210/endrev/bnaa004.
  10. Smith G.I., Mittendorfer B., Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest. 2019;129(10):3978–89. doi: 10.1172/JCI129186.
  11. Rijken M., Hujala A., van Ginneken E., et al. Managing multimorbidity: profiles of integrated care approaches targeting people with multiple chronic conditions in Europe. Health Policy. 2018;122(1):44–52. doi: 10.1016/j.health pol.2017.10.002.
  12. Dong G., Feng J., Sun F., et al. A global overview of genetically interpretable multimorbidities among common diseases in the UK Biobank. Gen Med. 2021;13(1):110. Doi: 10.1186/ s13073-021-00927-6.
  13. Garin N., Koyanagi A., Chatterji S., et al. Global Multimorbidity Patterns: A Cross-Sectional, Population-Based, Multi-Country Study. J Gerontol. Series A, Biol Sci Med Sci. 2016;71(2):205–14. doi: 10.1093/gerona/glv128.
  14. Денисов И.Н., Заугольникова Т.В., Попова Т.С., Морозова Т.Е. Ретроспективный анализ коморбидности у пациентов с заболеваниями желудочно-кишечного тракта, проживающих в сельской местности. Эксперим. и клин. гастроэнтерология. 2018;154(6):69–73. [Denisov I.N., Zagolnikova T.V., Popova T.S., Morozova T.E. Retrospective analysis of comorbidity in patients with diseases of the gastrointestinal tract living in rural areas. Exp Clin Gastroenterol. 2018;154(6):69–73. (In Russ.)].
  15. Концевая А.В., Шальнова С.А., Драпкина О.М. Исследование ЭССЕ-РФ: эпидемиология и укрепление общественного здоровья. Кардиоваскулярная терапия и профилактика. 2021;20(5):2987. [Kontsevaya A.V., Shalnova S.A., Drapkina O.M. Research ESSAY-RF: epidemiology and strengthening of public health. Cardiovasc Ther Prevent. 2021;20(5):2987. (In Russ.)]. doi: 10.15829/1728- 8800-2021-2987.
  16. Гринштейн Ю.И., Шабалин В.В., Руф Р.Р. и др. Распространенность сочетания артериальной гипертонии и дислипидемии среди взрослого населения крупного Восточносибирского региона. Кардиоваскулярная терапия и профилактика. 2021;20(4):2865. [Grinstein Yu.I., Shabalin V.V., Ruf R.R., et al. The prevalence of a combination of arterial hypertension and dyslipidemia among the adult population of a large East Siberian region. Cardiovasc Ther Prevent. 2021;20(4):2865 (In Russ.)]. doi: 10.15829/1728-8800-2021-2865.
  17. Ховасова Н.О., Наумов А.В., Ткачева О.Н., Рузанова В.И. Коморбидность костно-мышечных заболеваний у пациентов старших возрастных групп. Русский медицинский журнал. 2022;6:7–11. [Khovasova N.O., Naumov A.V., Tkacheva O.N., Ruzanova V.I. Comorbidity of musculoskeletal diseases in patients of older age groups. Russian medical journal. 2022;6:7–11. (In Russ.)].
  18. Стародубов В.И., Эделева А.Н., Сабгайда Т.П. Полиморбидность лиц старших возрастных групп в городской и сельской местности нижегородской области. Успехи геронтологии. 2018;31(1):25–31. [Starodubov V.I., Edeleva A.N., Sabgaida T.P. Polymorbidity of older age groups in urban and rural areas of the Nizhny Novgorod region. Succes Gerontol. 2018;31(1):25–31. (In Russ.)].
  19. Брагина Е.Ю., Пузырев В.П. Генетическая канва герменевтики феномена сочетания болезней человека. Вавиловский журнал генетики и селекции. 2023;27(1):7–17. [Bragina E.Yu., Puzyrev V.P. Genetic outline of the hermeneutics of the diseases connection phenomenon in human. Vavilov J Gen Breeding. 2023;27(1):7–17. (In Russ.)]. doi: 10.18699/VJGB-23-03.
  20. Драпкина О.М., Концевая А.В., Калинина А.М. и др. Коморбидность пациентов с хроническими неинфекционными заболеваниями в практике врача-терапевта. Евразийское руководство. Кардиоваскулярная терапия и профилактика. 2024;23(3):3696. [Drapkina O.M., Kontsevaya A.V., Kalinina A.M., et al. Comorbidity of patients with noncommunicable diseases in general practice. Eurasian guidelines. Cardiovasc Ther Prevent. 2024;23(3):3696. (In Russ.)]. doi: 10.15829/1728-8800-2024-3996.
  21. Hohnloser S.H., Fudim M., Alexander J.H., et al. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight Insights From the ARISTOTLE Tria. Circulation. 2019;139:2292–300. doi: 10.1161/CIRCULATIONAHA.118.037955.
  22. Shah A., Isath A., Aronow W.S. Cardiovascular complications of diabetes. Expert Rev Endocrinol Metab. 2022;17(5):383–8. doi: 10.1080/17446651.2022.2099838.
  23. Алферова В.И., Мустафина С.В. Распространенность ожирения во взрослой популяции Российской Федерации (обзор литературы). Ожирение и метаболизм. 2022;19(1):96–105. [Alferova V.I., Mustafina S.V. The prevalence of obesity in the adult population of the Russian Federation (literature review). Obes Metab. 2022;19(1):96–105. (In Russ.)]. doi: 10.14341/omet12809.
  24. Лукьянов М.М., Андреенко Е.Ю., Марцевич С.Ю. и др. Больные с фибрилляцией предсердий в клинической практике: коморбидность, медикаментозное лечение и исходы (данные регистров РЕКВАЗА). Рациональная фармакотерапия в кардиологии. 2020;16(6):888–98. [Loukianov M.M., Andreenko E.Yu., Martsevich S.Yu., et al. Patients with Atrial Fibrillation in Clinical Practice: Comorbidity, Drug Treatment and Outcomes (Data from RECVASA Registries). Rational Pharmacother Cardiol. 2020;16(6):888–98 (In Russ.)]. doi: 10.20996/1819- 6446-2020-12-01.
  25. Bluher M. Metabolically Healthy Obesity. Endocr Rev. 2020;41(3):bnaa004. doi: 10.1210/endrev/bnaa004.
  26. Smith G.I., Mittendorfer B., Klein S. Metabolically healthy obesity: facts and fantasies. J Clin Invest. 2019;129(10):3978–89. doi: 10.1172/JCI129186.
  27. Bansal S., Zilberman D. Macrorelationship between Average Life Expectancy and Prevalence of Obesity: Theory and Evidence from Global Data. Agricultural Econom. 2020;51:403–27. doi: 10.1111/agec.12562.
  28. Ruze R., Liu T., Zou X., et al. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Front Endocrinol. 2023;14:1161521. doi: 10.3389/fendo.2023.1161521.
  29. Chobot A., Gorowska-Kowolik K., Sokolowska M., Jarosz-Chobot P. Obesity and diabetes-Not only a simple link between two epidemics. Diab Metab Res Rev. 2018;34(7):e3042. doi: 10.1002/dmrr.3042.
  30. Мустафина С.В., Винтер Д.А., Рымар О.Д. и др. Кардиометаболические факторы риска у лиц с ожирением и риск развития сахарного диабета 2 типа в 12-летнем проспективном исследовании. Атеросклероз. 2021;17(1):52–61. [Mustafina S.V., Vinter D.A., Rymar O.D., et al. Cardiometabolic risk factors in obese individuals and the risk of incident diabetes mellitus in 12-year prospective study. Ateroscleroz. 2021;17(1):52–61. (In Russ.)]. doi: 10.52727/2078-256X-2021-17-52-61.
  31. Magkos F., Fraterrigo G., Yoshino J., et al. Effects of Moderate and Subsequent Progressive Weight Loss on Metabolic Function and Adipose Tissue Biology in Humans with Obesity. Cell Metab. 2016;23:591–601.
  32. Куденцова Л.А., Давыдов Д.В., Чернавский С.В., Стремоухов А.А. Классификация сахарного диабета: новый взгляд на проблему. Лечащий врач. 2022;5–6(25):84–90. [Kudentsova L.A., Davydov D.V., Chernavsky S.V., Stremoukhov A.A. Classification of diabetes: a new view on the problem. Lechashchiy Vrach. 2022;5–6(25):84–90. (In Russ.)]. doi: 10.51793/OS.2022.25.6.015.
  33. Lin C.H., Shao L., Zhang Y.M., et al. An evaluation of liraglutide including its efficacy and safety for the treatment of obesityь Exp Opin Pharmacother. 2020;21(3):275–85. doi: 10.1080/14656566.2019.1695779.
  34. Milani I., Guarisco G., Chinucci M., et al. Sex-Differences in Response to Treatment with Liraglutide 3.0 mg. J Clin Med. 2024;13(12):3369. doi: 10.3390/jcm13123369.
  35. Alsafwani D.M., Alotaibi H.N., Alzaid J.A., et al. Liraglutide Effect on Weight, Glycated Hemoglobin, and Blood Pressure: A Single-Center Experience in the Eastern Province of Saudi Arabia. Cureus. 2022;14(3):e23554. doi: 10.7759/cureus.23554. Retraction in: Cureus. 2022;14(4):r57. doi: 10.7759/cureus.r57.
  36. Mirabelli M., Chiefari E., Caroleo P., et al. Long-Term Effectiveness of Liraglutide for Weight Management and Glycemic Control in Type 2 Diabetes. Int J Environ Res Public Health. 2019;17(1):207. doi: 10.3390/ijerph17010207.
  37. Батрак Г.А., Жабурина М.В. Применение сибутрамина в комбинации с метформином у женщин репродуктивного возраста с абдоминальным типом ожирения. Consilium Medicum. 2020;22(6):32–4. [Batrak G.A., Zhaburina M.V. The use of sibutramine and metformin combination in women of reproductive age with abdominal obesity. Consilium Medicum. 2020;22(6):32–34. (In Russ.)]. doi: 10.26442/20751753.2020.6.200302.
  38. Dedov I.I., Melnichenko G.A., Troshina E.A., et al. Body Weight Reduction Associated with the Sibutramine Treatment: Overall Results of the PRIMAVERA Primary Health Care Trial. Obes Facts. 2018;11:335–43.
  39. American Association of Clinical Endocrinologists and American College of Endocrinology Comprehensive Clinical Practice Guidelines for Medical Care of Patients with Obesity. Endocr Pract. 2016;22(Suppl. 3).
  40. Bischoff S.C., Barazzoni R., Busetto L., et al. European guideline on obesity care in patients with gastrointestinal and liver diseases - Joint ESPEN/UEG guideline. Clin Nutr. 2022;41(10):2364–405. doi: 10.1016/j.clnu.2022.07.003.
  41. Peynirci H. The clinical efficacyof orlistat in the treatment of obesity. Int J Res Med Sci. 2020;8:3881–5.
  42. Hanefeld M., Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes. Diab Obes Metab. 2002;4:415–23.
  43. Liu S., Lin X., Tao M., et al. Efficacy and safety of orlistat in male patients with overweight/obesity and hyperuricemia: results of a randomized, double-blind, placebo-controlled trial. Lipids Health Dis. 2024;23:77. doi: 10.1186/s12944-024-02047-7.
  44. Tak Y.J., Lee S.Y. Long-term efficacy and safety of anti-obesity treatment: where do we stand? Curr Obes Rep. 2021;10:14–30. doi: 10.1007/s13679-020-00422-w.
  45. Singh A.K., Singh R. Pharmacotherapy in obesity: a systematic review and meta-analysis of randomized controlled trials of anti-obesity drugs. Expert Rev Clin Pharmacol. 2020;13:53–64. doi: 10.1080/17512433.2020.1698291.
  46. Yanovski S.Z., Yanovski J.A. Long-term drug treatment for obesity: a systematic and clinical review. JAMA (Review). 2014;311(1):74–86. doi: 10.1001/jama.2013.281361.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Main options of oral sugar-lowering therapy in DM2

Download (214KB)
Indexing metadata
3. Fig. 2. Mechanism of action of sibutramine

Download (179KB)
Indexing metadata
4. Fig. 3. Mechanism of action of Goldline Plus

Download (158KB)
Indexing metadata

Copyright (c) 2024 Bionika Media